Literature DB >> 24338811

Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients.

Ryoko Yamada1, Naoki Hiramatsu, Tsugiko Oze, Naoki Morishita, Naoki Harada, Masanori Miyazaki, Takayuki Yakushijin, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Tatsuya Kanto, Norio Hayashi, Tetsuo Takehara.   

Abstract

The degree of liver fibrosis is strongly associated with the antiviral effect of interferon on chronic hepatitis C patients. In this study, the accuracy of acoustic radiation force impulse (ARFI) in assessing liver fibrosis and the association between liver stiffness using ARFI and antiviral effects were investigated. The 124 patients with chronic hepatitis C enrolled in this study included 94 with HCV genotype 1 and 40 (30%) with moderate fibrosis (METAVIR fibrosis score ≥ F2). Sixty-one patients received pegylated interferon (peg-IFN) plus ribavirin combination therapy and the treatment responses were assessed. The shear wave velocity (Vs value) by ARFI had a strong correlation with the histological fibrosis stage (P < 0.001). The AUROC of the Vs value, aspartate aminotransferase platelet ratio index and FIB4 for the diagnoses of moderate fibrosis (≥F2) were 0.890, 0.779, and 0.737, respectively. HCV genotype 1 patients with the TT allele of IL28B and with a low Vs value (<1.40 m/sec) who were treated with peg-IFN plus ribavirin therapy achieved a sustained virologic response at a rate of 79% (15/19), while all patients with the TG/GG allele of IL28B and a high Vs value (≥1.40 m/sec) experienced a non-virologic response (6/6). The Vs value measured by ARFI could not predict the treatment response for patients with HCV genotype 2. It is concluded that the combination of ARFI at cut off of 1.4 m/sec and IL28B may be useful for patients with chronic hepatitis C with genotype 1 treated with peg-IFN/ribavirin combination therapy.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  IL28B; chronic hepatitis C; liver fibrosis; pegylated interferon plus ribavirin combination therapy

Mesh:

Substances:

Year:  2013        PMID: 24338811     DOI: 10.1002/jmv.23840

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

Review 1.  Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions.

Authors:  Paul Kennedy; Mathilde Wagner; Laurent Castéra; Cheng William Hong; Curtis L Johnson; Claude B Sirlin; Bachir Taouli
Journal:  Radiology       Date:  2018-03       Impact factor: 11.105

2.  Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.

Authors:  Keisuke Osakabe; Naohiro Ichino; Toru Nishikawa; Hiroko Sugiyama; Miho Kato; Ai Shibata; Wakana Asada; Naoto Kawabe; Senju Hashimoto; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Toshiki Kan; Kazunori Nakaoka; Yuka Takagawa; Masashi Ohki; Takamitsu Kurashita; Tomoki Takamura; Kentaro Yoshioka
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

Review 3.  Virtual Touch™ Quantification to Diagnose and Monitor Liver Fibrosis in Hepatitis B and Hepatitis C: A NICE Medical Technology Guidance.

Authors:  Jennifer A Summers; Muralikrishnan Radhakrishnan; Elizabeth Morris; Anastasia Chalkidou; Tiago Rua; Anita Patel; Viktoria McMillan; Abdel Douiri; Yanzhong Wang; Salma Ayis; Joanne Higgins; Stephen Keevil; Cornelius Lewis; Janet Peacock
Journal:  Appl Health Econ Health Policy       Date:  2017-04       Impact factor: 2.561

4.  Low Pretreatment Acoustic Radiation Force Impulse Imaging (ARFI) Values Predict Sustained Virological Response in Antiviral Hepatitis C Virus (HCV) Therapy.

Authors:  Steffen Zopf; Lara Rösch; Peter C Konturek; Ruediger S Goertz; Markus F Neurath; Deike Strobel
Journal:  Med Sci Monit       Date:  2016-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.